文献速递泌尿男性生殖肿瘤

卡巴他赛联合卡铂治疗转移性去势抵抗性前列腺癌的随机1-2期试验

Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial.
PubMed 文献 · Lancet Oncol · 2019-09-09

BACKGROUND: Taxane-platinum combinations have shown promising activity in metastatic castration-resistant prostate cancers in single-group clinical studies but not in randomised trials.…

要点

  • 联合卡铂可改善转移性去势抵抗性前列腺癌的无进展生存期。
  • 联合组3-5级疲劳、贫血、中性粒细胞减少和血小板减少更常见。
  • 紫杉烷-铂类联合在晚期前列腺癌中具有临床获益,3期研究已计划。

核心结论

  • 在转移性去势抵抗性前列腺癌男性中,卡巴他赛联合卡铂较卡巴他赛单药改善了临床疗效。
  • 尽管联合组不良事件更常见,但治疗安全且总体耐受良好。

研究设计与样本

  • 1-2期开放标签随机研究,在两家中心纳入进展性转移性去势抵抗性前列腺癌男性。
  • 1期9例患者完成计划,确定最大耐受剂量为卡巴他赛25 mg/m2联合卡铂AUC 4 mg/mL per min。
  • 2期160例患者按1:1随机分配至卡巴他赛单药组(n=79)或联合卡铂组(n=81)。
  • 2期主要终点为研究者评估的无进展生存期。

主要发现

  • 2期最常见3-5级不良事件:疲劳(卡巴他赛组7/79[9%] vs 联合组16/81[20%])、贫血(3[4%] vs 19[23%])、中性粒细胞减少(3[4%] vs 13[16%])、血小板减少(1[1%] vs 11[14%])。
  • 无治疗相关死亡。

关键数值与推荐

  • 1期最大耐受剂量定义为6例中不超过1例发生剂量限制性毒性的最高剂量队列。
  • 1期未观察到剂量限制性毒性,故选择卡巴他赛25 mg/m2联合卡铂AUC 4 mg/mL per min进入2期。
  • 所有患者接受生长因子支持和口服泼尼松10 mg每日。

临床怎么用

  • 对于转移性去势抵抗性前列腺癌男性,卡巴他赛联合卡铂可作为改善无进展生存期的治疗选择。
  • 联合治疗时需监测疲劳、贫血、中性粒细胞减少和血小板减少等不良事件。

局限性

  • 为1-2期研究,样本量有限,2期仅160例患者。
  • 研究在两家中心开展,结论需3期随机研究进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Taxane-platinum combinations have shown promising activity in metastatic castration-resistant prostate cancers in single-group clinical studies but not in randomised trials. Distinct biological subsets of the disease might derive the greatest benefit from the addition of platinum. We aimed to determine whether adding carboplatin to cabazitaxel would improve the outcomes of men with metastatic castration-resistant prostate cancer. METHODS: We did a phase 1-2, open label, randomised study at two centres in men with progressive metastatic castration-resistant prostate cancer. In phase 1, patients received intravenous cabazitaxel 20-25 mg/m2 and intravenous carboplatin area under the curve (AUC) 3-4 mg/mL per min every 21 days. The maximum tolerated dose was defined as the highest dose cohort studied in which one of six or fewer patients experienced a dose-limiting toxicity. In phase 2, patients were randomly assigned (1:1) centrally by a computerised algorithm to intravenous cabazitaxel 25 mg/m2 with or without intravenous carboplatin AUC 4 mg/mL per min. All patients received growth factor support and oral prednisone 10 mg daily. The primary endpoints were the maximum tolerated dose of the combination in phase 1 and investigator-assessed progression-free survival in phase 2. This trial is registered at ClinicalTrials.gov, number NCT01505868. FINDINGS: Between Aug 17, 2012, and May 11, 2015, nine patients completed phase 1 as planned, and 160 were randomly assigned to cabazitaxel (n=79) or cabazitaxel plus carboplatin (n=81) in phase 2. During phase I, grade 3 adverse events were anaemia (n=2), fatigue (n=1), thrombocytopenia (n=1), hypomagnesaemia (n=1), diarrhoea (n=1), hypokalaemia (n=1), anorexia (n=1), and dehydration (n=1), and no grade 4 adverse events occurred. No dose-limiting toxicities were observed, therefore, a maximum tolerated dose of cabazitaxel of 25 mg/m2 and carboplatin of AUC 4 mg/mL per min was selected for phase 2. At a median follow-up of 31·0 months (IQR 20·5-37·1), the combination improved the median progression-free survival from 4·5 months (95% CI 3·5-5·7) to 7·3 months (95% CI 5·5-8·2; hazard ratio 0·69, 95% CI 0·50-0·95, p=0·018). In the phase 2 study, the most common grade 3-5 adverse events were fatigue (7 [9%] of 79 in the cabazitaxel group vs 16 [20%] of 81 in the combination group), anaemia (3 [4%] vs 19 [23%]), neutropenia (3 [4%] vs 13 [16%]), and thrombocytopenia (1 [1%] vs 11 [14%]). There were no treatment-related deaths. INTERPRETATION: Carboplatin added to cabazitaxel showed improved clinical efficacy compared with cabazitaxel alone for men with metastatic castration-resistant prostate cancer. Although adverse events were more common with the combination, the treatment was safe and generally well tolerated. Our data suggest that taxane-platinum combinations have a clinically beneficial role in advanced prostate cancer and a randomised phase 3 study is planned. FUNDING: Sanofi Genzyme, University of Texas MD Anderson Cancer Center Prostate Cancer Moon Shot Program, and Solon Scott III Prostate Cancer Research Fund.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Corn PG, Heath EI, Zurita A, et al. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial. Lancet Oncol. 2019. PMID: 31515154. doi:10.1016/S1470-2045(19)30408-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。